Although FGF23 monitoring is not yet included in the regular management of CKD-MBD, it is important to emphasize its role in the development of left ventricular hypertrophy (Richter and Faul, 2018), among other systemic effects (Vervloet, 2020), and its powerful inverse association with survival in CKD patients (Gutiérrez et al., 2008). The gene discussed is FGF23; the disease is chronic kidney disease.